Across TCGA pan-cancer cohorts, RNU6-1193P RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated RNU6-1193P data layer.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RNU6-1193P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-1193P expression acts as an unfavorable survival marker.
OV are the cancer types where RNU6-1193P RNA most reproducibly stratifies survival.